Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Segura Pacheco, Blanca ^a   Perez Cardenas, Enrique ^a   Taja Chayeb, Lucia ^a   Chavez Blanco, Alma ^a   Revilla Vazquez, Alma ^b   Benitez Bribiesca, Luis ^c   Duenas González, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CYTOTOXIC AGENT; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DOXORUBICIN; FLUOROURACIL; HYDRALAZINE; MULTIDRUG RESISTANCE PROTEIN 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; VERAPAMIL;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL LEVEL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DEMETHYLATION; DNA METHYLATION; DRUG ACCUMULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPIC VARIATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 33748967231     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-32     Document Type: Article

References (48)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Kelloff GJ, Sigman CC: New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005, 41:491-501.
3. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
4. Robertson KD: DNA methylation, methyltransferases and cancer. Oncogene 2001, 20:3139-3155.
5. Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
6. Okano M, Xie S, Li E: Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. Nucleic Acids Res 1998, 26:2536-2540.
7. Tate PH, Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993, 3:226-231.
8. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
9. Rountree MR, Bachman KE, Baylin SB: DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genet 2000, 25:269-277.
10. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
11. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50.
12. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-161.
13. Segura-Pacheco B, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Mariscal I, Chávez A, Acuña C, Salazar AM, Lizano M, Dueñas-González A: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003, 9:1596-1603.
14. Angeles E, Vázquez-Valadez VH, Vázquez-Valadez O, Velázquez-Sánchez AM, Ramírez A, Martínez L, Díaz-Barriga S, Romero-Rojas A, Cabrera G, López-Castañares R, Dueñas-González A: Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. Lett Drug Design Discov 2005, 4:282-286.
15. Arce C, Candelaria, M, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Duenas-Gonzalez A: Hydralazine target: From blood vessels to the epigenoma. J Transl Med 2006, 4:10.
16. Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E, Cetina L, Revilla-Vázquez A, Taja-Chayeb L, Chávez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Dueñas-González A: A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5:44.
17. Sandoval Guerrero K, Revilla Vazquez A, Segura-Pacheco B, Duenas-Gonzalez A: Determination of 5-methyl-cytosine and cytosine in tumor DNA samples of cancer patients. Electrophoresis 2005, 26:1057-1062.
18. Pogribny I, Yi P, James SJ: A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 1999, 262:624-628.
19. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR: Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem 1999, 274:24250-24256.
20. Nyce J: Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989, 49:5829-5836.
21. Nyce J, Mylott D, Leonard S, Willis L, Kataria A: Detection of drug-induced DNNA hypermethylation in human cells exposed to cancer chemotherapy agents. J Liq Chrom 1989, 12:1313-1321.
22. Mimnaugh EG, Fairchild CR, Fruehauf JP, Sinha BK: Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol 1991, 42:391-402.
23. Niiya M, Niiya K, Shibakura M, Asaumi N, Yoshida C, Shinagawa K, Teshima T, Ishimaru F, Ikeda K, Tanimoto M: Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. Oncology 2004, 67:310-319.
24. Oelke K, Richardson B: Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol 2004, 23:315-331.
25. Qiu YY, Mirkin BL, Dwivedi RS: Differential expression of DNA-methyltransferases in drug resistant murine neuroblastoma cells. Cancer Detect Prev 2002, 26:444-453.
26. Karpinets TV, Foy BD: Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis 2005, 26:1323-1334.
27. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA: The human DNA methyltransferases (Dnmts) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999, 27:2291-2298.
28. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179.
29. Girault I, Tozlu S, Lidereau R, Bieche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003, 9:4415-4422.
30. Li Y, Wu SL, Bu DF, Zhu Y, Zhu Q, Cao XH: The expression of DNA methyltransferase DNMT1, 3A and 3B inacute leukemia and myelodysplastic syndrome. Zhonghua Nei Ke Za Zhi 2003, 42:688-691.
31. Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB, Schuebel KE: De novo CpG island methylation in human cancer cells. Cancer Res 2006, 66:682-692.
32. Qiu YY, Mirkin BL, Dwivedi RS: Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 2005, 29:456-463.
33. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, Richardson B: Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003, 48:746-56.
34. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006, 6:2.
35. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 1988, 48:6365-6370.
36. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR: Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997, 3:2025-2032.
37. Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M, Wada M: Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 1999, 262:924-932.
38. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP: Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002, 22:1844-1857.
39. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, Kozuru M, Komatsu H, Ueda R, Kuwano M: Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998, 92:4296-4307.
40. Tada Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J, Nakagawa M, Naito S, Kuwano M: MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000, 6:4618-4627.
41. Desiderato L, Davey MW, Piper AA: Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet 1997, 23:391-400.
42. Ando T, Nishimura M, Oka Y: Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia 2000, 14:1915-1920.
43. Efferth T, Futscher BW, Osieka R: 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis 2001, 27:637-648.
44. Futscher BW, Dalton WS: Activation of MDR1 gene expression is associated with cytosine methylation of its CpG island [abstract]. AACR 1996, 37:315.
45. Mirrione A, Seree E, Rimet O, Barra Y: Hypomethylation and hypoexpression of the human MDR1 gene [abstract]. AACR 1996, 37:538.
46. Fryxell KB, McGee SB, Simoneaux DK, Willman CL, Cornwell MM: Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. Leukemia 1999, 13:910-917.
47. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, Couillault C, Lajemi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S: Deciphering cellular states of innate tumor drug responses. Genome Biol 2006, 7:R19.
48. Perez-Plasencia C, Duenas-Gonzalez A: Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 2006, 5:27.